References
[1]Tang B, Li H, Xia K, Jiang H, Pan Q, Shen L, et al. A novel mutation in KCNQ2 gene causes benign familial neonatal convulsions in a Chinese family[J]. J Neuro Sci, 2004, 221(1-2): 31-34.
[2]周熙惠, 马爱群, 刘小红, 黄辰, 张艳敏, 史瑞明. 良性家族性婴儿惊厥家系KCNQ2基因新突变[J]. 中华儿科杂志, 2006, 44(7): 487-491.
[3]Miceli F, Soldovieri MV, Martire M, Taglialatela M. Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs[J]. Curr Opin Pharmacol, 2008, 8(1): 65-74.
[4]Volkers L, Rook MB, Das JH, Verbeek NE, Groenewegen WA, van Kempen MJ, et al. Functional analysis of novel KCNQ2 mutations found in patients with benign familial neonatal convulsions[J]. Neurosci Lett, 2009, 462(1): 24-29.
[5]Viadero MT, Rubín E, Amigo T, González-Lamu~no D. Three generations of hereditary long-QT syndrome with complete penetrance caused by the p.G316E KCNQ1 mutation[J]. Pediatr Cardiol, 2011, 32(1): 102-104.
[6]Otto JF, Yang Y, Frankel WN, White HS, Wilcox KS. A spontaneous mutation involving Kcnq2 (Kv7.2) reduces M-current density and spike frequency adaptation in mouse CA1 neurons[J]. J Neurosci, 2006, 26(7): 2053-2059.
[7]Heron SE, Cox K, Grinton BE, Zuberi SM, Kivity S, Afawi Z, et al. Deletions or duplications in KCNQ2 can cause benign familial neonatal seizures[J]. J Med Genet, 2007, 44(12): 791-796.
[8]Uehara A, Nakamura Y, Shioya T, Hirose S, Yasukochi M, Uehara K. Altered KCNQ3 potassium channel function caused by the W309R pore-helix mutation found in human epilepsy[J]. J Membr Biol, 2008, 222(2): 55-63.
[9]Charlier C, Singh NA, Ryan SG, Lewis TB, Reus BE, Leach RJ, et al. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family[J]. Nat Genet, 1998, 18(1): 53-55.
[10]Sugiura Y, Nakatsu F, Hiroyasu K, Ishii A, Hirose S, Okada M, et al. Lack of potassium current in W309R mutant KCNQ3 channel causing benign familial neonatal convulsions (BFNC)[J]. Epilepsy Res, 2009, 84(1): 82-85.
[11]Seebohm G, Scherer CR, Busch AE, Lerche C. Identification of specific pore residues mediating KCNQ1 inactivation. A novel mechanism for long QT syndrome[J]. J Biol Chem, 2001, 276(17): 13600-13605.
[12]Seebohm G, Pusch M, Chen J, Sanguinetti MC. Pharmacological activation of normal and arrhythmia-associated mutant KCNQ1 potassium channels[J]. Circ Res, 2003, 93(10): 941-947.
[13]Dedek K, Fusco L, Teloy N, Steinlein OK. Neonatal convulsion and epileptic encephalopathy in an Italian family with a missense mutation in the fifth transmembrane region of KCNQ2[J]. Epilepsy Res, 2003, 54(1): 21-27.
[14]Borgatti R, Zucca C, Cavallini A, Ferrario M, Panzeri C, Castaldo P, et al. A novel mutation in KCNQ2 associated with BFNC, drug resistant epilepsy, and mental retardation[J]. Neurology, 2004, 63(1): 57-65.
[15]王家勤, 李红梅, 尹景岗, 张红亚, 李冲, 顾仁骏,等. 良性家族性婴儿惊厥一家系基因定位及钾离子通道基因测序研究[J]. 中华儿科杂志, 2002, 40(9): 513517.
[16]Ishii A, Fukuma G, Uehara A, Miyajima T, Makita Y, Hamachi A, et al. A de novo KCNQ2 mutation detected in nonfamilial benign neonatal convulsions[J]. Brain Dev, 2009, 31(1): 27-33.
[17]Neubauer BA, Waldegger S, Heinzinger J, Hahn A, Kurlemann G, Fiedler B, et al. KCNQ2 and KCNQ3 mutations contribute to different idiopathic epilepsy syndromes[J]. Neurology, 2008, 71(3): 177-183.
[18]Lange W, Geissend-rfer J, Schenzer A, Grtzinger J, Seebohm G, Friedrich T, et al. Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels[J]. Mol Pharmacol, 2009, 75(2): 272-280.